Search our Database of Scientific Publications and Authors

I’m looking for a

    808 results match your criteria Lymphomatoid Papulosis

    1 OF 17

    Aggressive cutaneous T-cell lymphomas.
    Semin Diagn Pathol 2016 Dec 24. Epub 2016 Dec 24.
    Ackerman Academy of Dermatopathology, 145 East 32nd, St 10th floor, New York, 10016, NY, USA. Electronic address:
    Cutaneous T cell lymphomas (CTCLs) are heterogeneous, with a prognosis determined in large part by combined clinical, histopathologic, and immunophenotypic features. They are classified under the WHO-EORTC classification of primary cutaneous lymphoma. Whether or not a patient diagnosed with CTCL will experience an aggressive course may not be completely predictable; however, certain subtypes have been proven to be associated with a poor response to therapy and/or short survival. Read More

    Follicular lymphomatoid papulosis with follicular mucinosis: a clinicopathologic study of 3 cases with literature review and conceptual reappraisal.
    J Cutan Pathol 2016 Dec 23. Epub 2016 Dec 23.
    Department of Dermatology, University of Iowa, Iowa City, Iowa.
    Lymphomatoid papulosis (LyP), characterized by recurring, waxing and waning, cutaneous papulonodules, is increasingly recognized to represent a heterogeneous collection of pathologically dissimilar subtypes. Recently, a follicular LyP variant was proposed, featuring folliculotropism. Folliculotropism by atypical lymphocytes is conventionally associated with follicular mucinosis and mycosis fungoides (MF), and review of the literature suggests co-occurrence of folliculotropism and follicular mucinosis in LyP to be rare, with only 3 cases identified to date. Read More

    A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
    Semin Diagn Pathol 2016 Nov 29. Epub 2016 Nov 29.
    Kempf und Pfaltz, Histologische Diagnostik, Zürich, Switzerland; Department of Dermatology, University Hospital Zurich, CH-8091, Zurich, Switzerland. Electronic address:
    Cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ T-LPD) represent a spectrum encompassing lymphomatoid papulosis (LyP), primary cutaneous anaplastic large-cell lymphoma (pcALCL) and borderline lesions. They share the expression of CD30 as a common phenotypic marker. They differ however in their clinical presentation, the histological features and clinical course. Read More

    Past, present and future of cutaneous lymphomas.
    Semin Diagn Pathol 2016 Nov 28. Epub 2016 Nov 28.
    Research Unit Dermatopathology, Department of Dermatology, Medical University of Graz, Auenbruggerplatz 8, 8036 Graz, Austria. Electronic address:
    Primary cutaneous lymphomas represent a broad group of diseases with different clinical, histopathological, phenotypic, molecular, and prognostic features. All cutaneous lymphomas share the same tropism of neoplastic lymphocytes for the skin, but precise classification is paramount for proper management of the patients. Primary cutaneous lymphomas are classified according to the schemes proposed by the European Organization for Research and Treatment of Cancer (EORTC)-Cutaneous Lymphomas Task Force together with the World Health Organization (WHO) in 2005, and the WHO classification of 2008 with the 2016 update. Read More

    Cutaneous lymphoma: Kids are not just little people.
    Clin Dermatol 2016 Nov - Dec;34(6):749-759. Epub 2016 Jul 10.
    Department of Dermatology, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030.
    Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin lymphomas that predominantly affect older patients. Onset of cutaneous lymphoma in childhood is rare, but it can present as early as the first decade of life. In both adults and children, the diagnosis of cutaneous lymphoma can be challenging because inflammatory dermatoses can mimic CTCL both clinically and histologically. Read More

    Lymphoma of the eyelid.
    Surv Ophthalmol 2016 Nov 26. Epub 2016 Nov 26.
    Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Electronic address:
    Lymphoma of the eyelid constitutes 5% of ocular adnexal lymphoma. In previously published cases, 56% of lymphomas of the eyelid are of B-cell origin and 44% are of T-cell origin. The most frequent B-cell lymphomas are extranodal marginal zone lymphoma (27 cases-14%) and diffuse large B-cell lymphoma (18 cases-9%). Read More

    Low-dose radiotherapy for primary cutaneous anaplastic large-cell lymphoma while on low-dose methotrexate.
    Cutis 2016 Oct;98(4):253-256
    Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.
    Primary cutaneous anaplastic large-cell lymphoma (pcALCL) is part of a spectrum of CD30+ primary cutaneous lymphoproliferative disorders (pcLPDs) that also includes lymphomatoid papulosis (LyP). Localized radiotherapy at doses of 34 to 44 Gy is first-line treatment of pcALCL, but the use of low-dose radiotherapy for pcALCL has not been reported. We present the case of a patient with a history of pcALCL/LyP who was treated with low-dose radiotherapy while on oral low-dose methotrexate (MTX) once weekly. Read More

    Histopathological aspects and differential diagnosis of CD8 positive lymphomatoid papulosis.
    J Cutan Pathol 2016 Nov 30;43(11):963-973. Epub 2016 Aug 30.
    1st Department of Pathology and Experimental Cancer Research Institute, Semmelweis University, Budapest, Hungary.
    Lymphomatoid papulosis (LyP) belongs to CD30+ lymphoproliferative disorders with indolent clinical course. Classic histological subtypes, A, B and C are characterized by the CD4+ phenotype, while CD8+ variants, most commonly classified as type D, were reported in recent years. We present 14 cases of CD8+ LyP. Read More

    CD30+ lymphoproliferative disorder with spindle-cell morphology.
    J Cutan Pathol 2016 Nov 26;43(11):1041-1044. Epub 2016 Aug 26.
    Department of Pathology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.
    Lymphomatoid papulosis (LyP) is classified as a CD30+ primary cutaneous lymphoproliferative disease. The phenotypic variability along the spectrum of CD30+ lymphoproliferative diseases is highlighted by the distinct histologic subtypes of LyP types A, B, C, and the more recently described types D, E, and F. We report the case of an elderly woman with a clinical presentation and histopathologic findings consistent with LyP, whose atypical CD30+ infiltrate uniquely demonstrated a spindle-cell morphology. Read More

    CD30 Positive Lymphomatoid Angiocentric Drug Reactions: Characterization of a Series of 20 Cases.
    Am J Dermatopathol 2016 Sep 19. Epub 2016 Sep 19.
    *Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, NY; †Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO; and ‡Department of Dermatology, University of California at Irvine, Orange, CA.
    Introduction: Lymphomatoid drug reactions are atypical T cell cutaneous lymphocytic infiltrates induced by pharmacological therapy. Due to phenotypic abnormalities, clonality, and their close clinical and morphologic resemblance to T cell lymphomas, these eruptions have been categorized as drug-associated reversible granulomatous T cell dyscrasias.

    Design: A total of 20 cases were encountered in which a diagnosis of CD30 lymphomatoid drug reaction was rendered. Read More

    Dermoscopy in General Dermatology: A Practical Overview.
    Dermatol Ther (Heidelb) 2016 Dec 9;6(4):471-507. Epub 2016 Sep 9.
    Department of Experimental and Clinical Medicine, Institute of Dermatology, University of Udine, Udine, Italy.
    Over the last few years, dermoscopy has been shown to be a useful tool in assisting the noninvasive diagnosis of various general dermatological disorders. In this article, we sought to provide an up-to-date practical overview on the use of dermoscopy in general dermatology by analysing the dermoscopic differential diagnosis of relatively common dermatological disorders grouped according to their clinical presentation, i.e. Read More

    Primary cutaneous CD30(+) lymphoproliferative disorders.
    J Dtsch Dermatol Ges 2016 Aug;14(8):767-82
    Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston Texas, U.S.A.
    Primary cutaneous CD30(+) lymphoproliferative disorders are the second most common group of cutaneous T-cell lymphomas (CTCL) and include lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Both disease entities share overlapping clinical, histopathological, and molecular features, thus representing a spectrum of cutaneous CD30(+) lymphoproliferative disorders. LyP may be distinguished from cALCL by clinicopathological correlation. Read More

    Synchronous Occurrence of Primary Cutaneous Anaplastic Large Cell Lymphoma and Squamous Cell Carcinoma.
    Ann Dermatol 2016 Aug 26;28(4):491-4. Epub 2016 Jul 26.
    Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
    CD30+ lymphoproliferative disorders (LPD) represent a spectrum of T-cell lymphoma including lymphomatoid papulosis and anaplastic large cell lymphoma (ALCL). Epidermis overlying cutaneous CD30+ LPD often shows epidermal hyperplasia, hyperkeratosis, crusting, and ulceration and it is difficult to distinguish from carcinoma such as keratoacanthoma (KA) or squamous cell carcinoma (SCC). Several cases of pseudocarcinomatous hyperplasia mimicking KA or SCC in CD30+ LPD have been reported. Read More

    Methotrexate-associated primary cutaneous CD30-positive cutaneous T-cell lymphoproliferative disorder: a case illustration and a brief review.
    Am J Blood Res 2016 18;6(1):1-5. Epub 2016 May 18.
    Division of Hematology and Medical Oncology, James Graham Brown Cancer Center, University of Louisville Health Sciences Center Louisville, Kentucky, USA.
    Methotrexate (MTX) is a commonly used anti-metabolite agent. Increased risk of lymphoproliferative disorders (LPD) in patients with rheumatoid arthritis (RA) has been documented with the prolonged use of immunosuppressive medications such as MTX. This is thought to be the result of immune dysregulation and/or chronic immune stimulation. Read More

    Regional lymphomatoid papulosis of the breast restricted to an area of prior radiotherapy.
    Cutis 2016 May;97(5):E15-9
    Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Spain.
    We report the case of a 59-year-old woman with type A regional lymphomatoid papulosis (LyP) that was localized to the left breast, a cutaneous area that had received radiotherapy for treatment of a carcinoma of the breast 5 years prior. This report is a rare example of regional LyP with all lesions located in an area of prior radiotherapy. Read More

    A child with mastocytosis and lymphomatoid papulosis.
    Clin Case Rep 2016 May 14;4(5):517-9. Epub 2016 Apr 14.
    Department of Dermatology and Allergy Centre Odense University Hospital Sdr. Boulevard 29, 5000 Odense C Denmark.
    A change in clinical behavior of a disease should prompt search for differential diagnoses. Here, the appearance of ulcerated skin nodules in a preexisting cutaneous mastocytosis revealed a concurrent lymphomatoid papulosis - a CD30+ lymphoproliferative skin disease with histological features of a malignant lymphoma, but with a benign self-healing course. Read More

    Lymphomatoid Papulosis in Children and Adolescents: A Systematic Review.
    Am J Clin Dermatol 2016 Aug;17(4):319-27
    Department of Dermatology, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030-4095, USA.
    Background: Lymphomatoid papulosis (LyP) is a lymphoproliferative disorder that is rare among adults and even rarer among children. In adults, LyP is associated with an increased risk of secondary lymphomas.

    Objective: The aim of this systematic review was to describe the clinical and histopathological features of LyP in children, to assess the risk of associated lymphomas, and to compare the disease to the adult form. Read More

    Differential NFATc1 Expression in Primary Cutaneous CD4+ Small/Medium-Sized Pleomorphic T-Cell Lymphoma and Other Forms of Cutaneous T-Cell Lymphoma and Pseudolymphoma.
    Am J Dermatopathol 2017 Feb;39(2):95-103
    Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.
    Background: Primary cutaneous CD4 small/medium-sized pleomorphic T-cell lymphoma (PCSTCL) has recently emerged as a distinct clinicopathological entity. Because of a considerable degree of overlap with pseudolymphoma, the diagnosis is often challenging. Preliminary studies suggest that nuclear upregulation of calcineurin/nuclear factor of activated T cells (NFAT) may play a role in lymphomagenesis. Read More

    Characterization of the tumor microenvironment in primary cutaneous CD30-positive lymphoproliferative disorders: a predominance of CD163-positive M2 macrophages.
    J Cutan Pathol 2016 Jul 8;43(7):579-88. Epub 2016 May 8.
    Kempf and Pfaltz Histologische Diagnostik, Zürich, Switzerland.
    Background: The tumor microenvironment is essential for tumor survival, growth and progression. There are only a few studies on the tumor microenvironment in cutaneous CD30-positive lymphoproliferative disorders.

    Methods: We assessed the composition of the tumor microenvironment using immunohistochemistry studies in skin biopsies from cases diagnosed with lymphomatoid papulosis (LyP: 18 specimens), primary cutaneous anaplastic large-cell lymphoma (PC-ALCL: 8 specimens), and reactive diseases harboring CD30-positive cells (18 specimens). Read More

    A Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder Arising in a Patient With Multiple Myeloma and Cutaneous Amyloidosis.
    Am J Dermatopathol 2016 May;38(5):388-92
    *Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; †Department of Dermatology, Mayo Clinic, Rochester, MN, Dr. Cohen is now affiliated with the Department of Pathology and Immunology, Baylor College of Medicine, and Department of Pathology, Michael E. DeBakey Veterans Affairs Hospital, Houston, TX (As of/After July 1, 2015); ‡Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN; and §Departments of Laboratory Medicine and Pathology, and Dermatology, Mayo Clinic, Rochester, MN.
    CD30-positive cutaneous lymphoproliferative disorders, a group of T-cell neoplasms, including lymphomatoid papulosis (LyP) and cutaneous anaplastic large cell lymphoma, require careful clinicopathologic correlation for diagnosis. An association between LyP and the development of a second hematolymphoid malignancy has been established in the literature. LyP has also been reported with systemic amyloidosis, but no such reports have documented coexisting cutaneous amyloid deposition with LyP to our knowledge. Read More

    Type D lymphomatoid papulosis simulating aggressive epidermotropic cytotoxic lymphoma.
    Indian J Pathol Microbiol 2016 Jan-Mar;59(1):81-3
    Department of Dermatology, Christian Medical College, Vellore, Tamil Nadu, India.
    Three histological subtypes of lymphomatoid papulosis (LyP), type A (histiocytic), type B (mycosis fungoides like) and type C (anaplastic large cell lymphoma like) are well recognized. Two new histological variants, type D (simulating an aggressive epidermotropic cytotoxic lymphoma) and type E (angioinvasive type) has been described recently. We describe a 27-year-old man presented with a history of asymptomatic erythematous papules on both upper and lower limbs noted since 10 years of age. Read More

    Primary Cutaneous Anaplastic Large-Cell Lymphoma With 6p25.3 Rearrangement in a Cardiac Transplant Recipient: A Case Report and Review of the Literature.
    Am J Dermatopathol 2016 Jun;38(6):461-5
    *Department of Pathology and Laboratory Medicine, NewYork Presbyterian Hospital-Weill Cornell Medical Center, New York, NY; and †Dermatocor, Bostwick Laboratories, Uniondale, NY.
    Posttransplant lymphoproliferative disorders define an important form of lymphoproliferative disease causally linked with a state of iatrogenic immune dysregulation inherent to the posttransplant setting. Most posttransplant lymphoproliferative disorders are in the context of Epstein-Barr virus-associated B-cell lymphoproliferative disease, most notably diffuse large-cell B-cell lymphoma. A less common variant falls under the rubric of posttransplant T-cell lymphoproliferative disease, which is largely unrelated to Epstein-Barr virus infection. Read More

    [Lymphomatoid papulosis: a clinicopathologic study of 22 cases].
    Zhonghua Yi Xue Za Zhi 2015 Dec;95(46):3750-2
    Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China.
    Objective: To investigate the clinical presentation, histopathological features, progression, and treatment of lymphomatoid papulosis (LyP).

    Methods: A retrospective review was performed on clinicopathological data of 22 patients diagnosed with LyP from June 2010 to March 2015 in Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College.

    Result: The mean age of the 22 LyP patients was 39 years (range: 7-83 years). Read More

    Lymphomatoid Papulosis Type D: Report of a Case in a Child and Review of the Literature.
    Pediatr Dermatol 2016 Mar-Apr;33(2):e52-6. Epub 2016 Jan 14.
    Department of Pathology, School of Medicine and Dentistry, University of Rochester, Rochester, New York.
    Lymphomatoid papulosis (LyP) is a cutaneous CD30-positive T-cell lymphoproliferative disorder that occurs primarily in adults and presents with crops of papules that become necrotic and spontaneously regress. It is classified according to the histopathologic findings; currently recognized subtypes include A, B, C, D, and E. LyP is uncommon in children. Read More

    Follicular Lymphomatoid Papulosis: An Eosinophilic-Rich Follicular Subtype Masquerading as Folliculitis Clinically and Histologically.
    Am J Dermatopathol 2016 Jan;38(1):e1-10
    Departments of *Dermatology and Cutaneous Biology; †Surgery, Thomas Jefferson University, Philadelphia, PA; and ‡Dermatologist and Dermatopathologist, Bryn Mawr Skin and Cancer Institute, Main Line Health, Bryn Mawr, PA.
    Lymphomatoid papulosis (LyP) is an uncommon CD30 lymphoproliferative disorder with a relatively excellent prognosis. Ten to twenty percent of cases, however, are associated with a lymphoma, typically systemic or cutaneous anaplastic large cell lymphoma, mycosis fungoides, or Hodgkin lymphoma. Subtypes divide LyP into infiltrate-descriptive categories along a spectrum of histological manifestation. Read More

    Pseudocarcinomatous Hyperplasia Hiding Lymphomatoid Papulosis: A "Low-Power View" Pitfall.
    Int J Surg Pathol 2016 May 27;24(3):232-6. Epub 2015 Dec 27.
    Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
    Pseudocarcinomatous hyperplasia (PCH) is a reactive proliferation of the epidermis that can be associated with many inflammatory and neoplastic conditions. Histologically, it is characterized by irregular strands of epidermis, usually at the level of the follicular infundibulum, projecting downward into the dermis. The differentiation between a well-differentiated squamous cell carcinoma and PCH can be particularly challenging when the biopsy is superficial and the causing lesion is dermal-based. Read More

    Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis.
    Oncologist 2016 Jan 14;21(1):76-83. Epub 2015 Dec 14.
    Department of Dermatology, Rouen University Hospital and INSERM U 519, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, Normandy, France.
    Background: Lymphomatoid papulosis (LyP) is classified as an indolent cutaneous lymphoma, but outcome dramatically worsens if LyP is associated with lymphoma. The frequency of this association remains unclear in the literature. Here, we assess the frequency and risk factors of association between LyP and another lymphoma in an 11-year retrospective study conducted in 8 dermatology departments belonging to the French Study Group on Cutaneous Lymphoma (FSGCL). Read More

    Lymphomatoid papulosis with pseudocarcinomatous hyperplasia in a 7-year-old girl: a case report.
    J Cutan Pathol 2016 May 7;43(5):430-3. Epub 2015 Dec 7.
    Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.
    Lymphomatoid papulosis (LyP) belongs to the group of cutaneous CD30+ lymphoproliferative disorders. Pseudocarcinomatous hyperplasia has rarely been reported in patients with LyP. In this report, we describe a case of LyP presenting as pseudocarcinomatous hyperplasia. Read More

    Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients.
    J Am Acad Dermatol 2016 Jan 28;74(1):59-67. Epub 2015 Oct 28.
    Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
    Background: Lymphomatoid papulosis (LyP) is a CD30(+) lymphoproliferative disorder, with a self-regressing clinical course and malignant histopathology.

    Objective: The aim of this study was to evaluate characteristics, risk factors, associated malignancies, long-term outcome, and treatment of LyP in a large cohort representing the experience of the MD Anderson Cancer Center.

    Methods: Patient charts and clinical and histopathologic data of 180 patients with LyP were retrospectively assessed. Read More

    Characterization of primary cutaneous CD8+/CD30+ lymphoproliferative disorders.
    Am J Dermatopathol 2015 Nov;37(11):822-33
    *Department of Dermatology, New York University School of Medicine, New York, NY; †Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA; ‡San Diego Pathologists Medical Group, Los Angeles, CA; §Department of Dermatology, University of Chicago Pritzker School of Medicine; and ¶Department of Pathology, Southern California Permanente Medical Group, Sunset Medical Center, Los Angeles, CA.
    CD30 primary cutaneous lymphoproliferative diseases include both lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (PCALCL). The neoplastic cell of most primary CD30 lymphoproliferative disorders is CD4 positive. The terminology LyP "type D" has been used to describe a growing number of cases of LyP with a predominantly CD8 infiltrate. Read More

    Practical Management of CD30⁺ Lymphoproliferative Disorders.
    Dermatol Clin 2015 Oct 29;33(4):819-33. Epub 2015 Aug 29.
    University of Alabama at Birmingham, 1530 3rd Avenue South, EFH 414, Birmingham, AL 35294, USA. Electronic address:
    Primary cutaneous CD30⁺ lymphoproliferative disorders (LPDs) account for approximately 25% of cutaneous lymphomas. Although these LPDs are clinically heterogeneous, they can be indistinguishable histologically. Lymphomatoid papulosis rarely requires systemic treatment; however, multifocal primary cutaneous anaplastic large cell cutaneous lymphoma and large cell transformation of mycosis fungoides are typically treated systemically. Read More

    Intralymphatic Spread Is a Common Finding in Cutaneous CD30+ Lymphoproliferative Disorders.
    Am J Surg Pathol 2015 Nov;39(11):1511-7
    *Research Unit Dermatopathology, Department of Dermatology, Medical University of Graz, Graz, Austria †Anatomic Pathology Unit, Gaetano Rummo Hospital, Benevento ‡Dermatology Unit, University of Sassari, Sassari §Department of Dermatopathology, San Gallicano Dermatology Institute, Rome, Italy.
    An intralymphatic variant of the cutaneous CD30 lymphoproliferative disorders (cutaneous anaplastic large cell lymphoma [ALCL] and lymphomatoid papulosis [LyP]) has been described recently. We retrieved 60 cases of ALCL of the skin (primary cutaneous: 37; cases with concomitant involvement of 1 regional lymph node: 4; skin involvement from systemic disease: 4; cases with staging results unknown: 15) and 16 cases of LyP, to evaluate the presence of lymphatic vessel involvement by neoplastic cells. A D2-40 immunohistochemical staining was used to highlight lymphatic vessels. Read More

    Primary Cutaneous CD8(+) CD30(+) Anaplastic Large Cell Lymphoma: An Unusual Case with a High Ki-67 index-A Short Review.
    Indian J Dermatol 2015 Jul-Aug;60(4):373-7
    Department of Pathology, Medical College and Sir Sayajirao General Hospital, Baroda, Gujarat, India.
    Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a part of the spectrum of CD30(+) cutaneous lymphoproliferative disorder, characterized by variable degrees of CD2, CD3, CD4 and CD5 expression by lymphoid cells. PCALCLs with an expression of cytotoxic phenotype (CD8(+)) and cytotoxic proteins are uncommon. Cutaneous CD8(+) CD30(+) lymphoproliferative lesions are difficult to classify, diagnose and may be the cause of misdiagnose. Read More

    Methotrexate for topical application in an extemporaneous preparation.
    J Dtsch Dermatol Ges 2015 Sep 18;13(9):891-901. Epub 2015 Aug 18.
    Institute for Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
    Background: The antifolate agent methotrexate is routinely used for systemic therapy of cancer and chronic inflammatory diseases. Successful topical use has been described for individual therapeutic attempts, in case series, and small studies, especially for mycosis fungoides (premycotic stage) and lymphomatoid papulosis. With respect to its clinical use in selected treatment scenarios, there have been no approved preparations or regulated instructions for pharmaceutical compounding. Read More

    New variant lymphomatoid papulosis type E preceding and coexisting with mycosis fungoides - a case report and review of the literature.
    J Cutan Pathol 2015 Aug 14. Epub 2015 Aug 14.
    Department of Pathology and Laboratory Medicine, University of Louisville School of Medicine, Louisville, KY, USA.
    Angioinvasive (type E) lymphomatoid papulosis (LyP) is a recently described subtype of LyP presenting with eschar-like lesions that can be mistaken for aggressive forms of angiocentric cutaneous T-cell lymphoma. None of the cases of angioinvasive LyP described thus far have been associated with mycosis fungoides (MF). Herein, we describe a case of angioinvasive LyP type E coexisting with MF. Read More

    Evaluation of the 2008 World Health Organization classification for non-mycosis fungoides, non-Sezary syndrome T/NK-cell lymphomas with primary cutaneous involvement.
    J Cutan Pathol 2015 Aug 13. Epub 2015 Aug 13.
    Department of Dermatology, University of São Paulo Medical School, Sao Paulo, Brazil.
    Background: Cutaneous non-mycosis fungoides non-Sezary syndrome T/NK cell lymphomas (non-MF/non-SS CTCL) are rare. In 2005, a consensus of the World Health Organization (WHO) and European Organization for Research and Treatment of Cancer (EORTC) classifications for primary cutaneous lymphomas was established. These guidelines were then adopted into the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008. Read More

    Multiple cutaneous lymphoproliferative disorders showing a retained tumor clone by T-cell receptor gene rearrangement analysis: a case series of four patients and review of the literature.
    Int J Dermatol 2016 Feb 12;55(2):e62-71. Epub 2015 Aug 12.
    Departments of Pathology, Dermatopathology, Dermatology, and Clinical Pathology, University of Virginia Health System, Charlottesville, VA, USA.
    Background: Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma (CTCL), followed by CD30+ lymphoproliferative disorders, including lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL). The objective was to report on a series of patients with different types of CTCL at different times in their clinical course, with a focus on clonality studies.

    Methods: Four patients with multiple diagnoses of CTCLs were identified. Read More

    Atypical cutaneous γδ T cell proliferation with morphologic features of lymphoma but with clinical features and course of PLEVA or lymphomatoid papulosis.
    J Cutan Pathol 2015 Aug 12. Epub 2015 Aug 12.
    Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
    Reactive lymphoid infiltrates of the skin composed predominantly of gamma-delta (γδ) T cells are not well described in the literature. Herein we report a case of an otherwise healthy 4-year-old male who presented with a waxing and waning papular rash characterized by small, discrete crusted papules spread across his trunk, face and extremities. Clinical evaluation revealed no evidence of systemic disease. Read More

    1 OF 17